Theodore Tselios

TL;DR: Go back to the basics to understand the immunopathophysiology of MS to gain insights in the development of new improved drug treatments and present current disease-modifying therapies for the treatment of MS.

TL;DR: Important cyclic peptide compounds used as synthetic immunogens, transmembrane ion channels, antigens for Herpes Simplex Virus, and potential immunotherapeutic vaccines for diabetes are reviewed.

TL;DR: Evidence that the soluble and transmembrane forms of tumour necrosis factor exert opposing deleterious and beneficial effects, respectively, in a multiple sclerosis model is presented and it is suggested that selective inhibition of soluble tumour Necrosis factor may provide a new way forward for the treatment of multiple sclerosis and possibly other inflammatory central nervous system disorders.

TL;DR: The rational design and synthesis of cyclic peptide analogues has turned into an alternative approach for improved biological activity in the case of metabolically unstable peptide ligands.

TL;DR: Two cyclic analogues of the immunodominant myelin basic protein peptide, designed by NMR and molecular modeling data on human MBP(87-99) and its linear antagonist peptide analogue, inhibited EAE in Lewis rats and decreased inflammation in the spinal cord.